There would be a lot going on behind the scenes. The deal with Cephalon involved great rapport. Teva possibly less so and when that happened and why is unclear. Certainly Teva is powering away with conventional pharmaceutical drugs. So either they don't get MSB stem cells or they have some fixations, or both.
SI's strategy seems to be to concentrate on getting to market some very lucrative lines early, and having the other ones well developed and able to be negotiated on, and then being able to capitalise on the halo effect of being at market, or very close to. The next results from Stage 3 clinical trials will be pivotal to that IMO. In that respect having a range of other applications at an earlier stage of development is not a negative. We want funding to take them to those later stages, and the more the better. Which is why the extension of the Celgene option to include more applications was a positive. (How some prominent posters managed to turn it into a negative is testament to the parallel universe that chat sometimes occupies).
So the negotiations with Celgene and other partners will hit their stride I would think once those results are out. Then things will really begin to turn, along with income from Japan, and from the US registration of aGVHD and that revenue as well.
All IMO.
MSB Price at posting:
$1.67 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)